Hodgkin Lymphoma News and Research

RSS

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

16 Oct 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

14 Aug 2023

GEMINI test shows promise for early detection of lung cancer

Novel blood testing technology being developed by researchers at the Johns Hopkins Kimmel Cancer Center that combines genome-wide sequencing of single molecules of DNA shed from tumors and machine learning may allow earlier detection of lung and other cancers.

4 Aug 2023

Medicaid expansion under the ACA linked to increased palliative care use

More people with advanced cancers in the United States received critical palliative care services, according to new findings by researchers at the American Cancer Society (ACS).

5 Jul 2023

Arima Genomics continues momentum toward clinic with formation of clinical advisory board

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to improve human health and drive discovery in the life sciences, today announced the formation of a clinical advisory board to help the company advance its 3D genomics technologies into the clinical oncology and biopharmaceutical markets.

From Arima Genomics, Inc. 5 Jul 2023

Research shows fertility challenges for women treated for childhood Hodgkin lymphoma

Women treated for childhood Hodgkin lymphoma may face declining fertility at a younger age, according to research presented today (Monday) at the 39th annual meeting of the European Society of Human Reproduction and Embryology.

26 Jun 2023

Pandemic restrictions associated with a significant drop in cancer diagnoses

Pandemic restrictions corresponded with a significant drop in diagnoses of breast, colorectal and prostate cancers as well as melanoma, according to a new Alberta study published in CMAJ (Canadian Medical Association Journal)

12 Jun 2023

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

5 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

New data guides treatment choices for patients with r/r lymphoma during pregnancy

Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%.

1 Jun 2023

Novel treatment targets against natural killer/T-cell lymphoma identified

A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has discovered that a transcription factor, TOX2, was aberrantly increased in patients with Natural killer/T-cell lymphoma (NKTL).

29 May 2023

Combination treatment shows promise for aggressive subtype of non-Hodgkin lymphoma

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

5 May 2023

Montana considers requiring insurance to cover fertility preservation for cancer patients

Katie Beall was diagnosed with breast cancer on March 1, 2022. Two days later, doctors told her the chemotherapy she needed would make her infertile.

28 Apr 2023

How to increase your social network as you age

Friends sitting around a table, talking and laughing. A touch on the arm, as one of them leans over to make a confiding comment. A round of hugs before walking out the door.

28 Apr 2023

Exposure to 4 or more CT scans before adulthood doubles the risk for cancers

For children under age 18 years, a single computed tomography (CT) scan is not associated with an increased risk of brain tumors, leukemia or lymphoma, but exposure to 4 or more scans before adulthood more than doubles the risk, according to new research https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221303 in CMAJ.

24 Apr 2023